DeepEvidence: AI Agents Move Beyond Answer Retrieval to Weigh Scientific Evidence

Biomedical science has quietly crossed a threshold that few researchers anticipated even a decade ago. The bottleneck in discovery is no longer the generation or availability of data. Genomics, proteomics, high-throughput screening and clinical records now produce evidence at a rate that dwarfs any individual’s capacity to read, let alone integrate. Writing in Nature Machine Intelligence, Shruti Shikhare, Jake Cohen-Setton and Krishna C. Bulusu argue that the decisive challenge of the coming decade is not finding information but organizing it — weighing contradictory findings, tracing chains of support and exposing the assumptions buried in thousands of publications. Their commentary accompanies the emergence of DeepEvidence, a deep research agent designed to move beyond the answer-centric paradigm that has defined search engines and, more recently, large language model assistants.

The distinction the authors draw is subtle but consequential. Conventional retrieval systems, including the retrieval-augmented generation pipelines that power most current AI assistants, treat a scientific question as a lookup problem: locate documents that match a query, extract passages and compose a fluent answer. This architecture works well when the answer exists in a single source and the user knows what to ask. It fails, however, when a question sits at the intersection of conflicting evidence — when one study reports that a kinase drives tumor proliferation, another finds it dispensable, and a third implicates it in immune evasion. In such cases, a fluent answer can mask genuine scientific uncertainty, presenting a consensus that does not exist or smoothing over contradictions that a careful reviewer would flag immediately.

DeepEvidence represents a different design philosophy. Rather than optimizing for the best answer, the system constructs explicit representations of scientific evidence as it explores the literature. Each claim encountered is captured together with its supporting data, the experimental context in which it was established, the methods that produced it and its relationships to other claims. The agent then navigates this structured evidence landscape, pursuing lines of inquiry the way an experienced investigator might: following citations forward and backward, identifying where findings replicate or diverge, and noting when a conclusion rests on a single experiment or a particular cell line. The output is not a paragraph of prose but an organized map of what is known, how well it is known and where the gaps lie.

The timing of this shift is no accident. The past several years have produced a rapid succession of AI systems aimed at accelerating science. Autonomous laboratory agents such as the Coscientist work from Boiko and colleagues demonstrated that large language models could plan and execute chemical experiments. AlphaFold, described by Jumper and colleagues, transformed structural biology by predicting protein structures at scale. More recently, AI co-scientist systems from Google and the Zou lab at Stanford have shown that language models can generate hypotheses, propose experiments and even prioritize drug candidates, with some suggestions validated in the laboratory. Deep research products from major AI companies have made multi-step literature investigation available to millions of users. Each of these advances, however, has largely preserved the answer-centric frame: the system is asked a question and returns a result.

What the commentary’s authors — researchers at AstraZeneca’s oncology division and Turbine Simulated Cell Systems — bring to the discussion is a practitioner’s view of why that frame breaks down in drug discovery. Target identification, the process of selecting the molecular targets that a new drug will modulate, is perhaps the most evidence-intensive decision in the pharmaceutical pipeline. A target that looks compelling in one dataset may collapse under the weight of contradictory clinical evidence, and the cost of pursuing the wrong target is measured in years and hundreds of millions of dollars. The authors’ position, informed by their work in oncology research and development, is that the value of an AI system in this setting lies precisely in its ability to surface the structure of disagreement: which evidence is strong, which is weak, which claims depend on specific model systems and which conclusions have been quietly overturned by later work.

Technically, the move from retrieval to evidence synthesis demands several capabilities that current systems handle poorly. First, the agent must maintain provenance — a record of where each piece of information came from and under what conditions it was obtained. Second, it must represent uncertainty explicitly, distinguishing a meta-analysis of dozens of trials from a single underpowered study. Third, it must reason across modalities, connecting textual claims in papers to structured data in databases, to molecular interaction networks and to computational models of cellular behavior. Knowledge graphs and semantic data integration, long a staple of biomedical informatics, provide one substrate for this, but the commentary suggests that the deeper requirement is an agent architecture in which evidence organization is a first-class objective rather than a byproduct of answer generation.

The authors situate DeepEvidence within a broader trajectory they describe as a shift from answer-centric systems to evidence-organizing systems. In their framing, the first generation of scientific AI tools automated lookup; the second generation automated reasoning over retrieved content; and the emerging third generation automates the construction of the evidence base itself — the painstaking work of synthesis that currently occupies systematic reviewers, meta-analysts and senior investigators. This is not a replacement for human judgment but a reorganization of labor. If an agent can assemble a defensible, traceable account of the evidence surrounding a biological question in hours rather than months, the human experts who review that account can spend their attention on the interpretive decisions that genuinely require expertise: judging biological plausibility, weighing clinical context and deciding what experiment to run next.

The implications extend well beyond oncology. Evidence synthesis is the core activity of systematic review in medicine, of regulatory assessment, of environmental risk evaluation and of technology forecasting — anywhere that decisions must rest on the totality of published findings rather than a single study. The volume of scientific publication, now measured in millions of articles per year, has made comprehensive manual synthesis increasingly untenable; the replication crisis has simultaneously made uncritical synthesis dangerous. An agent that can represent the quality and consistency of evidence, rather than merely its presence, addresses both problems at once. The commentary’s authors are careful to note the open challenges: evaluation of such systems is difficult because ground truth in contested scientific areas is itself uncertain, and the risk of confident but subtly wrong synthesis is real.

There is also a cultural dimension to the argument. Scientific training rewards the production of answers — results, conclusions, claims. The infrastructure of publication reinforces this, indexing papers by findings rather than by the evidence that supports them. A shift toward evidence exploration asks researchers, funders and publishers to value the organization of knowledge as a contribution in its own right. The authors’ perspective, coming from industry rather than academia, reflects a setting in which the cost of poor synthesis is felt directly and quickly. In pharmaceutical research and development, an agent that reliably distinguishes robust evidence from noise is not an intellectual luxury; it is a competitive necessity that determines which programs advance and which are abandoned.

Whether DeepEvidence and its successors fulfill this promise will depend on rigorous, transparent evaluation — benchmarks that test not whether an agent produces a plausible answer but whether its evidence maps hold up under expert scrutiny. But the conceptual shift the commentary articulates is likely to endure regardless of any single system’s fate. The era in which an AI assistant could impress by retrieving the right fact is ending. The era in which it will be judged by its ability to tell scientists what the evidence actually shows — with all its contradictions, caveats and open questions intact — has begun. For a field drowning in its own literature, that may be the most important capability yet.

Subject of Research: Deep research agents for evidence exploration and synthesis in biomedical discovery

Article Title: Shifting from knowledge retrieval to evidence exploration and synthesis

Article References: Shikhare, S., Cohen-Setton, J., & Bulusu, K. C. (2026). Shifting from knowledge retrieval to evidence exploration and synthesis. Nature Machine Intelligence. https://doi.org/10.1038/s42256-026-01313-w

Image Credits: AI Generated

DOI: 10.1038/s42256-026-01313-w

Keywords: DeepEvidence, deep research agents, biomedical discovery, evidence synthesis, knowledge retrieval, large language models, target identification, data integration, knowledge graphs, machine learning, drug discovery, scientific reasoning